Prodrug approaches for CNS delivery

AAPS Journal

Volumn 10, Issue 1, 2008, Pages 92-102

  Rautio, Jarkko ^a   Laine, Krista ^a   Gynther, Mikko ^a   Savolainen, Jouko ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Fennopharma Ltd   (Finland)

Author keywords

BBB; CNS; Delivery drug; Prodrug

Indexed keywords

1,4 DIHYDROTRIGONELLINE; 4 CHLOROKYNURENINE; 7 CHLOROKYNURENIC ACID; AMPRENAVIR; CHLORAMBUCIL; CHLORAMBUCIL TERT BUTYL ESTER; DOPAMINE; DRUG CARRIER; ELACRIDAR; ESTRADIOL; FLUOROURACIL; GABAPENTIN; GANCICLOVIR; GLYCOPROTEIN P INHIBITOR; KETOPROFEN; KYNURENIC ACID; LANIQUIDAR; LEVODOPA; MELPHALAN; MERCAPTOPURINE; PENICILLIN G; PHENYLALANINE; PROBENECID; PRODRUG; PSILOCIN; PSILOCYBINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TARIQUIDAR; UNINDEXED DRUG; ZIDOVUDINE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG UPTAKE; GENE DIRECTED ENZYME PRODRUG THERAPY; GLIOBLASTOMA; HUMAN; LIPOPHILICITY; MENOPAUSAL SYNDROME; MONOTHERAPY; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODRUGS;

EID: 51249101710     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9009-8     Document Type: Review

References (104)

1. W. M. Pardridge. Why is the global CNS pharmaceutical market so under-penetrated. Drug Discov. Today. 7(1):5-7 (2002), Jan 1.
2. W. M. Pardridge. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2(1):3-14 (2005), Jan.
3. D. J. Begley. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther. 104(1):29-45 (2004), Oct.
4. M. W. Bradbury. The structure and function of the blood-brain barrier. Fed. Proc. 43(2):186-190 (1984), Feb.
5. R. C. Janzer, and M. C. Raff. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 325(6101):253-257 (1987). Jan 15-21.
6. J. H. Kim, J. H. Kim, J. A. Park, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J. Biochem. Mol. Biol. 39(4):339-345 (2006), Jul 31.
7. C. H. Lai, and K. H. Kuo. The critical component to establish in vitro BBB model: Pericyte. Brain Res. Brain Res. Rev. 50(2):258-265 (2005), Dec 15.
8. D. J. Begley. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48(2):136-146 (1996), Feb.
9. W. Loscher, and H. Potschka. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2(1):86-98 (2005), Jan.
10. A. H. Schinkel. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug. Deliv. Rev. 36(2-3):179-194 (1999), Apr 5.
11. D. J. Begley. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10(12):1295-1312 (2004).
12. W. M. Pardridge, and W. H. Oldendorf. Transport of metabolic substrates through the blood-brain barrier. J. Neurochem. 28 (1):5-12 (1977), Jan.
13. W. M. Pardridge. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Curr. Opin. Drug. Discov. Devel. 6(5):683-691 (2003), Sep.
14. T. Halmos, M. Santarromana, J. Herscovici, and D. Scherman. Brain drug delivery through the blood-brain barrier transport systems. Attempted strategies and issues. STP Pharma. Sci. 7:37-42 (1997).
15. C. Yang, G. S. Tirucherai, and A. K. Mitra. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. 1(2):159-175 (2001), Mar.
16. W. M. Pardridge. Blood-brain barrier delivery. Drug Discov. Today. 12(1-2):54-61 (2007), Jan.
17. A. Albert. Chemical aspects of selective toxicity. Nature. 182:421-422 (1958).
18. A. A. Sinkula, and S. H. Yalkowsky. Rationale for design of biologically reversible drug derivatives: Prodrugs. J. Pharm. Sci. 64(2):181-210 (1975), Feb.
19. V. J. Stella, W. N. Charman, and V. H. Naringrekar. Prodrugs. Do they have advantages in clinical practice? Drugs. 29(5):455-473 (1985), May.
20. V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag, and J. W. Tilley. Prodrugs: Challenges and Rewards. Vol. 1-2. Published by AAPS Press and Springer, New York, (2007).
21. R. F. Sherwood. Advanced drug delivery reviews: Enzyme prodrug therapy. Adv. Drug Del. Rev. 22:269-288 (1996).
22. V. Stella. Prodrug strategies for improving drug-like properties. In R. Borchardt, M. Hageman, J. Stevens, E. Kerns, and D. Thakker (eds.), Optimizing the "drug-like" properties of leads in drug discovery, Springer, New York, 2006, pp. 221-242.
23. V. J. Stella. Prodrugs as therapeutics. Expert Opin. Ther. Patents. 14(3):277-280 (2004).
24. V. J. Stella, and K. W. Nti-Addae. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59:677-694 (2007), May 29.
25. J. Rautio, H. Kumpulainen, T. Heimbach, et al. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discovery. 7:1-16 (2008), Mar.
26. T. Järvinen, J. Rautio, M. Masson, and T. Loftsson. Design and pharmaceutical applications of prodrugs. In S. Gad (ed.), Drug discovery handbook. John Wiley & Sons, Inc., Hoboken, 2005, pp. 733-796.
27. K. Beaumont, R. Webster, I. Gardner, and K. Dack. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr. Drug Metab. 4(6):461-485 (2003), Dec.
28. M. W. Brightman, and T. S. Reese. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell. Biol. 40(3):648-677 (1969), Mar.
29. B. D. Anderson. Prodrug approaches for drug delivery to the brain. In V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag, and J. W. Tilley (eds.), Prodrugs: Challenges and Rewards. Part 1. AAPS Press/ Springer, New York, 2007, 573-651.
30. W. H. Oldendorf, S. Hyman, L. Braun, and S. Z. Oldendorf. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 178(64):984-986 (1972), Dec 1.
31. B. D. Anderson. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev. 19:171-202 (1996).
32. N. H. Greig, S. Genka, E. M. Daly, D. J. Sweeney, and S. I. Rapoport. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol. 25(5):311-319 (1990).
33. S. Genka, J. Deutsch, U. H. Shetty et al. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin Exp Metastasis. 11(2):131-140 (1993), Mar.
34. N. Bodor, and P. Buchwald. Drug targeting via retrometabolic approaches. Pharmacol. Ther. 76(1-3):1-27 (1997), Oct-Dec.
35. N. Bodor, and P. Buchwald. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36(2-3):229-254 (1999), Apr 5.
36. N. Bodor, and P. Buchwald. Barriers to remember: Brain-targeting chemical delivery systems and Alzheimer's disease. Drug. Discov. Today. 7(14):766-774 (2002), Jul 15.
37. L. Prokai, K. Prokai-Tatrai, and N. Bodor. Targeting drugs to the brain by redox chemical delivery systems. Med. Res. Rev. 20(5):367-416 (2000), Sep.
38. M. E. Brewster, W. R. Anderson, D. O. Helton, N. Bodor, and E. Pop. Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharm. Res. 12(5):796-798 (1995), May.
39. M. E. Brewster, W. R. Anderson, A. I. Webb et al. Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob Agents Chemother. 41(1):122-128 (1997), Jan.
40. M. E. Brewster, K. Raghavan, E. Pop, and N. Bodor. Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob. Agents. Chemother. 38(4):817-823 (1994), Apr.
41. W. M. Wu, E. Pop, E. Shek, and N. Bodor. Brain-specific chemical delivery systems for beta-lactam antibiotics. In Vitro and in vivo studies of some dihydropyridine and dihydroisoquinoline derivatives of benzylpenicillin in rats. J. Med. Chem. 32(8):1782-1788 (1989), Aug.
42. W. M. Wu, E. Pop, E. Shek, R. Clemmons, and N. Bodor. Brain and CSF specific chemical delivery systems for beta-lactam antibiotics. Study of two dihydropyridine derivatives of benzylpenicillin in rabbits and dogs. Drug Des. Deliv. 7(1):33-43 (1990), Dec.
43. K. S. Estes, M. E. Brewster, J. W. Simpkins, and N. Bodor. A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats. Life Sci. 40(13):1327-1334 (1987), Mar 30.
44. G. Mullersman, H. Derendorf, M. E. Brewster, K. S. Estes, and N. Bodor. High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats. Pharm. Res. Mar. 5(3):172-177 (1988).
45. D. K. Sarkar, S. J. Friedman, S. S. Yen, and S. A. Frautschy. Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17 beta in female rats. Neuroendocrinology. 50(2):204-210 (1989), Aug.
46. T. Ishikura, T. Senou, H. Ishihara, T. Kato, and T. Ito. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds. Int. J. Pharm. 116(1):51 (1995).
47. X. Tan, F. D. Boudinot, C. K. Chu, et al. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a bispivaloylthioethyl prodrug for intracellular delivery of zidovudine monophosphate, in mice. Antivir. Chem. Chemother. 11(3):203-211 (2000), May.
48. G. Somogyi, P. Buchwald, and N. Bodor. Targeted drug delivery to the central nervous system via phosphonate derivatives (anionic delivery system for testosterone). Pharmazie. 57(2):135-137 (2002), Feb.
49. G. Somogyi, S. Nishitani, D. Nomi, P. Buchwald, L. Prokai, and N. Bodor. Targeted drug delivery to the brain via phosphonate derivatives: I. Design, synthesis and evaluation of an anionic chemical delivery system for testosterone. Int. J. Pharm. 166(1):15 (1998).
50. G. Somogyi, P. Buchwald, D. Nomi, L. Prokai, and N. Bodor. Targeted drug delivery to the brain via phosphonate derivatives II. Anionic chemical delivery system for zidovudine (AZT). Int. J. Pharm. 166(1):27 (1998).
51. H. Chen, F. Noble, B. P. Roques, and M. C. Fournie-Zaluski. Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs. J. Med. Chem. 44(21):3523-3530 (2001), Oct 11.
52. I. Tamai, and A. Tsuji. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89(11):1371-1388 (2000), Nov.
53. B. S. Anand, S. Dey, and A. K. Mitra. Current prodrug strategies via membrane transporters/receptors. Expert. Opin. Biol. Ther. 2(6):607-620 (2002), Aug.
54. S. Majumdar, S. Duvvuri, and A. K. Mitra. Membrane transporter/ receptor-targeted prodrug design: Strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 56(10):1437-1452 (2004), Jun 23.
55. W. M. Pardridge. Drug targeting to the brain. Pharm. Res. 24(9):1733-1744 (2007), Sep.
56. R. J. Boado, J. Y. Li, M. Nagaya, C. Zhang, and W. M. Pardridge. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Natl. Acad. Sci. U S A. 96(21):12079-12084 (1999), Oct 12.
57. R. Duelli, B. E. Enerson, D. Z. Gerhart, and L. R. Drewes. Expression of large amino acid transporter LAT1 in rat brain endothelium. J. Cereb. Blood Flow Metab. 20(11):1557-1562 (2000), Nov.
58. Q. R. Smith. Carrier-mediated transport to enhance drug delivery to brain. International Congress Series. 1277: 63-74 (2005).
59. K. C. Cundy, R. Branch, T. Chernov-Rogan, et al. XP13512 [(+/-)-1- ([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 311(1):315-323 (2004), Oct.
60. G. J. Goldenberg, H. Y. Lam, A. Begleiter. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 254(4):1057-1064 (1979), Feb 25.
61. C. Fernandez, O. Nieto, J. A. Fontenla, E. Rivas, M. L. de Ceballos, A. Fernandez-Mayoralas. Synthesis of glycosyl derivatives as dopamine prodrugs: Interaction with glucose carrier GLUT-1. Org. Biomol. Chem. 1(5):767-771 (2003), Mar 7.
62. P. Gomes, P. Soares-da-Silva. L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res. 829(1-2):143-150 (1999), May 22.
63. W. Dairman, J. G. Christenson, S. Udenfriend. Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa. Proc. Natl. Acad. Sci. U S A. 68(9):2117-2120 (1971), Sep.
64. I. Mena, G. C. Cotzias. Protein intake and treatment of Parkinson's disease with levodopa. N. Engl. J. Med. 292(4):181-184 (1975), Jan 23.
65. M. Hokari, H. Q. Wu, R. Schwarcz, Q. R. Smith. Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport. 8(1):15-18 (1996), Dec 20.
66. D. M. Killian, S. Hermeling, P. J. Chikhale. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv. 14(1):25-31 (2007), Jan.
67. Q. R. Smith, and A. J. L. Cooper. Mammalian amino acid transport. Plenum Press, New York, 1992, pp. 165-193.
68. I. Walker, D. Nicholls, W. J. Irwin, and S. Freeman. Drug delivery via active transport at the blood-brain barrier: Affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int. J. Pharm. 104(2):157 (1994).
69. A. Balakrishnan, B. Jain-Vakkalagadda, C. Yang, D. Pal, and A. K. Mitra. Carrier mediated uptake of -tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC) - strategy for the design of transporter/receptor targeted prodrugs. Int. J. Pharm. 247 (1-2):115 (2002).
70. C. L. Farrell, and W. M. Pardridge. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: An electron microscopic immunogold study. Proc. Natl. Acad. Sci. U. S. A. 88(13):5779-5783 (1991), Jul 1.
71. G. Battaglia, M. La Russa, V. Bruno, et al. Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. 860(1-2):149-156 (2000), Mar 31.
72. T. Halmos, M. Santarromana, K. Antonakis, and D. Scherman. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur. J. Pharmacol. 318(2-3):477-484 (1996), Dec 30.
73. C. Fernandez, O. Nieto, E. Rivas, G. Montenegro, J. A. Fontenla, and A. Fernandez-Mayoralas. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr. Res. 327(4):353-365 (2000), Aug 7.
74. F. Bonina, C. Puglia, M. G. Rimoli, et al. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: Synthesis, pharmacological activity and in vitro stability studies. J. Drug Target. 11(1):25-36 (2003), Jan.
75. S. Ohtsuki, and T. Terasaki. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24(9):1745-1758 (2007), Sep.
76. G. Lee, S. Dallas, M. Hong, and R. Bendayan. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53(4):569-596 (2001), Dec.
77. A. Tsuji, and I. I. Tamai. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug. Deliv. Rev. 36(2-3):277-290 (1999), Apr 5.
78. T. Ooie, T. Terasaki, H. Suzuki, and Y. Sugiyama. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J. Pharmacol. Exp. Ther. 283(1):293-304 (1997), Oct.
79. W. Loscher, and H. Potschka. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1):22-76 (2005), May.
80. K. P. Moore, H. Zhu, H. A. Rajapakse, et al. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 17(21):5831-5835 (2007), Nov 1.
81. S. R. Stauffer, M. G. Stanton, A. R. Gregro, et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation. Bioorg. Med. Chem. Lett. 17(6):1788-1792 (2007), Mar 15.
82. J. W. Polli, J. L. Jarrett, S. D. Studenberg, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16(8):1206-1212 (1999), Aug.
83. P. Breedveld, J. H. Beijnen, and J. H. Schellens. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27(1):17-24 (2006), Jan.
84. Y. Deguchi, H. Hayashi, S. Fujii, et al. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: A preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. Eur J Pharm Sci 8:371-378 (2000).
85. P. K. Kiptoo, M. O. Hamad, P. A. Crooks, and A. L. Stinchcomb. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J. Control. Release. 113(2):137-145 (2006), Jun 28.
86. J. Leppanen, J. Huuskonen, T. Nevalainen, J. Gynther, H. Taipale, and T. Jarvinen. Design and synthesis of a novel L-dopa-entacapone codrug. J. Med. Chem. 45(6):1379-1382 (2002), Mar 14.
87. E. M. Taylor. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41 (2):81-92 (2002).
88. U. Bickel, T. Yoshikawa, and W. M. Pardridge. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug. Deliv. Rev. 46(1-3):247-279 (2001), Mar 1.
89. W. M. Pardridge. Vector-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 36(2-3):299-321 (1999), Apr 5.
90. Y. Saito, J. Buciak, J. Yang, and W. M. Pardridge. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc. Natl. Acad. Sci. U S A. 92(22):10227-10231 (1995), Oct 24.
91. U. Bickel, T. Yoshikawa, E. M. Landaw, K. F. Faull, and W. M. Pardridge. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. U S A. 90(7):2618-2622 (1993), Apr 1.
92. O. Greco, and G. U. Dachs. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J. Cell. Physiol. 187(1):22-36 (2001), Apr.
93. G. U. Dachs, J. Tupper, and G. M. Tozer. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs. 16(4):349-359 (2005), Apr.
94. M. Aghi, F. Hochberg, and X. O. Breakefield. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2(3):148-164 (2000), May-Jun.
95. W. A. Denny. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Invest. 22(4):604-619 (2004).
96. K. J. Pulkkanen, and S. Yla-Herttuala. Gene therapy for malignant glioma: Current clinical status. Mol. Ther. 12(4):585-598 (2005), Oct.
97. Z. H. Wang, S. Samuels, M. A. Gama Sosa, and E. H. Kolodny. 5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon. J Neurooncol. 36(3):219-229 (1998), Feb.
98. N. G. Rainov. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene. Ther. 11(17):2389-2401 (2000), Nov 20.
99. N. G. Rainov, and H. Ren. Clinical trials with retrovirus mediated gene therapy-what have we learned?. J. Neurooncol. 65(3):227-236 (2003), Dec.
100. A. Immonen, M. Vapalahti, K. Tyynela, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol. Ther. 10(5):967-972 (2004), Nov.
101. A. M. Sandmair, S. Loimas, P. Puranen, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene. Ther. 11(16):2197-2205 (2000), Nov 1.
102. P. Ettmayer, G. L. Amidon, B. Clement, and B. Testa. Lessons learned from marketed and investigational prodrugs. J Med Chem. 47(10):2393-2404 (2004), May 6.
103. V. J. Stella. A Case for Prodrugs. In: Stella VJ, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J, eds. Prodrugs: Challenges and Rewards. Part 1. AAPS Press/Springer, New York, 2007, pp. 3-33.
104. M. Gynther, K. Laine, J. Ropponen, et al. Large neutral amino acid transporter enables brain drug delivery via prodrug. J. Med. Chem. (2008), In press.